Trial Profile
Randomized, Double-blind, Placebo-controlled Study of the Effect of a Single Injection of SAR164877 (REGN475) on Reduction of Pain From Vertebral Fracture Associated With Osteoporosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 May 2013
Price :
$35
*
At a glance
- Drugs Fasinumab (Primary)
- Indications Musculoskeletal pain
- Focus Therapeutic Use
- 22 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Dec 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 30 Oct 2009 New trial record